Diagnosed gastroparesis, ileus, and intestinal obstruction or pseudo-obstruction requiring emergency, hospital, or specialist care are the injuries most consistently described as qualifying for review. Eli Lilly states Zepbound is its tirzepatide injection for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity Eli Lilly prescribing information. Federal cases alleging these gut injuries were centralized as MDL No.
3094 in the Eastern District of Pennsylvania. The U.S. Judicial Panel on Multidistrict Litigation ordered that transfer in February 2024 JPML transfer order.
Official resources:
- Read the official notice from Uscourts — Use this primary source to verify the official announcement.
- Read the official guidance from Lilly — Use this primary source to verify the official guidance.
Table of Contents
- Which gut injuries are under review?
- What records support a claim?
- Where does the litigation stand?
- What falls outside this case?
Which gut injuries are under review?
The core group is diagnosed stomach paralysis, slowed or blocked gut movement, and bowel blockage. Gastroparesis means the stomach empties too slowly. Ileus means the intestines briefly stop moving. Obstruction or pseudo-obstruction means food and fluid cannot pass normally.
Court reporting describes these injuries as qualifying for review when a doctor diagnosed them and the patient needed emergency, hospital, or specialist care. A brief bout of nausea after an injection is not the same pattern. The focus is on objective injury plus higher-level treatment. Eli Lilly's label warns that use is linked to sometimes-severe gastrointestinal reactions. It also says Zepbound was not studied in patients with severe gastroparesis and is not recommended for them.
What records support a claim?
Claimants still need prescription proof, objective testing or diagnosis, and treatment records, according to Eastern District of Pennsylvania docket reporting via MDL Update. That file decides whether a firm can evaluate causation, injury, and damages.
Gather these items in one folder: Testing matters because symptoms alone rarely move a file forward. Gastric-emptying studies, CT scans, and specialist notes tie the diagnosis to care. Keep a timeline of shots, symptoms, and missed work or meals.
- pharmacy printout showing Zepbound fills and dates
- test results and diagnosis note for gastroparesis, ileus, or obstruction
- emergency, hospital, or gastroenterology visit records
Where does the litigation stand?
MDL No. 3094 includes Zepbound and tirzepatide claims against Eli Lilly alongside Novo Nordisk claims. It sits before Judge Karen S. Marston in the Eastern District of Pennsylvania.
MDL Update reported about 4,025 pending actions in October 2026 MDL 3094 case tracker. There is no bellwether trial schedule or settlement. General-causation expert hearings were held September 14-18, 2026, with no ruling reported. That posture leaves the burden on each claimant's prescription, diagnosis, and treatment file.
What falls outside this case?
Sudden vision-loss claims for NAION are not part of MDL 3094. The Judicial Panel consolidated them separately as MDL No. 3163 in December 2025, also before Judge Marston.
MDL Update reported 247 pending cases in October 2026 MDL 3163 case tracker. Do not file a gut-injury claim for vision loss in this track. Pull pharmacy records now, ask for complete test images and visit notes, and bring them to a case review.